Biologic therapies for inflammatory disease

Emily M. Berger; Alice B. Gottlieb

doi:10.1007/978-1-84800-165-7_28

Biologic therapies for inflammatory disease

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Biologics are approved for the therapy of psoriasis and psoriatic arthritis as well as a number of nondermatologic indications. Biologics include cell adhesion molecule antagonists (alefacept and efalizumab) and cytokine antagonists (etanercept, infliximab, and adalimumab). Biologics appear relatively safe, but clinical and laboratory monitoring of safety is recommended. Cytokine (i.e., tumor necrosis factor) antagonists have other potential uses in dermatology, including pyoderma gangrenosum, hidrandenitis suppurativa, and sarcoidosis. Future biologics will include interleukin-12/ interleukin- 23-targeted therapies.

Original language	English
Title of host publication	Clinical and Basic Immunodermatology
Publisher	Springer London
Pages	481-526
Number of pages	46
ISBN (Print)	9781848001640
DOIs	https://doi.org/10.1007/978-1-84800-165-7_28
State	Published - 2008
Externally published	Yes

Access to Document

10.1007/978-1-84800-165-7_28

Cite this

@inbook{d1c8e82a716b4a3ba7db53960ffc4089,

title = "Biologic therapies for inflammatory disease",

abstract = "Biologics are approved for the therapy of psoriasis and psoriatic arthritis as well as a number of nondermatologic indications. Biologics include cell adhesion molecule antagonists (alefacept and efalizumab) and cytokine antagonists (etanercept, infliximab, and adalimumab). Biologics appear relatively safe, but clinical and laboratory monitoring of safety is recommended. Cytokine (i.e., tumor necrosis factor) antagonists have other potential uses in dermatology, including pyoderma gangrenosum, hidrandenitis suppurativa, and sarcoidosis. Future biologics will include interleukin-12/ interleukin- 23-targeted therapies.",

author = "Berger, {Emily M.} and Gottlieb, {Alice B.}",

year = "2008",

doi = "10.1007/978-1-84800-165-7_28",

language = "English",

isbn = "9781848001640",

pages = "481--526",

booktitle = "Clinical and Basic Immunodermatology",

publisher = "Springer London",

address = "United Kingdom",

}

TY - CHAP

T1 - Biologic therapies for inflammatory disease

AU - Berger, Emily M.

AU - Gottlieb, Alice B.

PY - 2008

Y1 - 2008

N2 - Biologics are approved for the therapy of psoriasis and psoriatic arthritis as well as a number of nondermatologic indications. Biologics include cell adhesion molecule antagonists (alefacept and efalizumab) and cytokine antagonists (etanercept, infliximab, and adalimumab). Biologics appear relatively safe, but clinical and laboratory monitoring of safety is recommended. Cytokine (i.e., tumor necrosis factor) antagonists have other potential uses in dermatology, including pyoderma gangrenosum, hidrandenitis suppurativa, and sarcoidosis. Future biologics will include interleukin-12/ interleukin- 23-targeted therapies.

AB - Biologics are approved for the therapy of psoriasis and psoriatic arthritis as well as a number of nondermatologic indications. Biologics include cell adhesion molecule antagonists (alefacept and efalizumab) and cytokine antagonists (etanercept, infliximab, and adalimumab). Biologics appear relatively safe, but clinical and laboratory monitoring of safety is recommended. Cytokine (i.e., tumor necrosis factor) antagonists have other potential uses in dermatology, including pyoderma gangrenosum, hidrandenitis suppurativa, and sarcoidosis. Future biologics will include interleukin-12/ interleukin- 23-targeted therapies.

UR - http://www.scopus.com/inward/record.url?scp=84890184585&partnerID=8YFLogxK

U2 - 10.1007/978-1-84800-165-7_28

DO - 10.1007/978-1-84800-165-7_28

M3 - Chapter

AN - SCOPUS:84890184585

SN - 9781848001640

SP - 481

EP - 526

BT - Clinical and Basic Immunodermatology

PB - Springer London

ER -

Biologic therapies for inflammatory disease

Abstract

Access to Document

Fingerprint

Cite this